GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (STU:038) » Definitions » Other Current Payables

NovoCure (STU:038) Other Current Payables : €69.8 Mil (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is NovoCure Other Current Payables?

NovoCure's Other Current Payables for the quarter that ended in Mar. 2024 was €69.8 Mil.

NovoCure's quarterly Other Current Payables declined from Sep. 2023 (€72.6 Mil) to Dec. 2023 (€0.0 Mil) but then increased from Dec. 2023 (€0.0 Mil) to Mar. 2024 (€69.8 Mil).


NovoCure Other Current Payables Historical Data

The historical data trend for NovoCure's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Other Current Payables Chart

NovoCure Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NovoCure Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.86 62.35 72.61 - 69.84

NovoCure Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.


NovoCure Other Current Payables Related Terms

Thank you for viewing the detailed overview of NovoCure's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.


NovoCure (STU:038) Business Description

Traded in Other Exchanges
Address
Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. Products are comprised of two main components: electric field generator and arrays and related accessories. NovoCure derives its major revenues in the United States.

NovoCure (STU:038) Headlines

No Headlines